Updating an institutional chest pain algorithm: Incorporating new evidence on emerging pharmacotherapy

Critical Pathways in Cardiology

Volumn 11, Issue 3, 2012, Pages 107-113

  Rosner, Gregg F ^a   Stone, Gregg W ^a   Stant, Jennifer ^a   Burr, Jennifer ^a   Tirado, Amelia ^a   Collins, Michael ^a   Moses, Jeffrey ^a   Leon, Martin B ^a   Giglio, James ^a   Rabbani, Leroy E ^a  

^a NewYork Presbyterian Hospital   (United States)

Author keywords

acute coronary syndromes; acute myocardial infarction; clinical pathways; clopidogrel; prasugrel; rivaroxaban; ticagrelor

Indexed keywords

ACETYLSALICYLIC ACID; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE; ENOXAPARIN; EPTIFIBATIDE; HIRULOG; METOPROLOL; OMEPRAZOLE; PHENYTOIN; PRASUGREL; RIFAMPICIN; RIVAROXABAN; ROSUVASTATIN; TICAGRELOR; TICLOPIDINE; WARFARIN;

ALGORITHM; ARTICLE; BLEEDING; CARDIAC PATIENT; CLINICAL PATHWAY; COLOMBIA; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; DYSPNEA; GASTRODUODENAL ULCER; HUMAN; INSTITUTIONALIZATION; LOADING DRUG DOSE; NON ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; THORAX PAIN; UNITED STATES; UNIVERSITY HOSPITAL; UNSTABLE ANGINA PECTORIS;

ACUTE CORONARY SYNDROME; ALGORITHMS; ANTICOAGULANTS; CHEST PAIN; CRITICAL PATHWAYS; ELECTROCARDIOGRAPHY; EVIDENCE-BASED EMERGENCY MEDICINE; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; PLATELET AGGREGATION INHIBITORS;

EID: 84864360574     PISSN: 1535282X     EISSN: 15352811     Source Type: Journal    
DOI: 10.1097/HPC.0b013e31825f8da0     Document Type: Article

References (27)

1. Galper BZ, Stant J, Reilly M, et al. Updating the chest pain algorithm: incorporating new evidence on emerging antiplatelet agents. Crit Pathw Cardiol. 2011;10:9-16.
2. Press Announcements FDA approves blood-thinning drug Brilinta to treat acute coronary syndromes. http://www.fda.gov/NewsEvents/Newsroom/ PressAnnouncements/ucm263964.htm. Accessed March 4, 2012.
3. Wright RS, Anderson JL, Adams CD, et al. 2011 ACCF/AHA focused update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST- Elevation Myocardial Infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines developed in collaboration with the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol. 2011;57:1920-1959.
4. Kushner FG, Hand M, Smith SC Jr, et al. 2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2009;54:2205-2241.
5. Balsano F, Rizzon P, Violi F, et al. Antiplatelet treatment with ticlopidine in unstable angina. A controlled multicenter clinical trial. The Studio della Ticlopidina nell'Angina Instabile Group. Circulation. 1990;82:17-26. (Pubitemid 20216311)
6. Berger PB, Bell MR, Rihal CS, et al. Clopidogrel versus ticlopidine after in-tracoronary stent placement. J Am Coll Cardiol. 1999;34:1891-1894. (Pubitemid 30002640)
7. Yusuf S, Zhao F, Mehta SR, Chrolavicius S, Tognoni G, Fox KK. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001;345:494-502. (Pubitemid 32758501)
8. Erratum, N Engl J Med 2001;345:1506, 1716.
9. Plavix (clopidogrel bisulfate) tablets prescribing information. http://products. sanof.us/plavix/plavix.html. Accessed February 25, 2012.
10. Mega JL, Close SL, Wiviott SD, et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med. 2009;360:354-362.
11. Scheen AJ. Cytochrome P450-mediated cardiovascular drug interactions. Expert Opin Drug Metab Toxicol. 2011;7:1065-1082.
12. Shuldiner AR, O'Connell JR, Bliden K P, et al. Association of cytochrome P450 2C19 genotype with the antiplatelet effect and clinical effcacy of clopi-dogrel therapy. JAMA. 2009;302:849-857.
13. http://pi.lilly.com/us/effent.pdf. Accessed March 4, 2012.
14. Wallentin L, Varenhorst C, James S, et al. Prasugrel achieves greater and faster P2Y12receptor-mediated platelet inhibition than clopidogrel due to more effcient generation of its active metabolite in aspirin-treated patients with coronary artery disease. Eur Heart J. 2008;29:21-30.
15. Wiviott SD, Trenk D, Frelinger AL, et al.; PRINCIPLE-TIMI 44 Investigators. Prasugrel compared with high loading-and maintenance-dose clopidogrel in patients with planned percutaneous coronary intervention: the Prasugrel in Comparison to Clopidogrel for Inhibition of Platelet Activation and Aggregation-Thrombolysis in Myocardial Infarction 44 trial. Circulation. 2007;116:2923-2932. (Pubitemid 350291199)
16. http://www.astrazeneca-us.com/pi/brilinta.pdf. Accessed March 4, 2012.
17. Storey R F, Husted S, Harrington RA, et al. Inhibition of platelet aggregation by AZD6140, a reversible oral P2Y12 receptor antagonist, compared with clopidogrel in patients with acute coronary syndromes. J Am Coll Cardiol. 2007;50:1852-1856. (Pubitemid 350017792)
18. Husted S, Emanuelsson H, Heptinstall S, Sandset PM, Wickens M, Peters G. Pharmacodynamics, pharmacokinetics, and safety of the oral reversible P2Y12 antagonist AZD6140 with aspirin in patients with atherosclerosis: a double-blind comparison to clopidogrel with aspirin. Eur Heart J. 2006;27:1038-1047.
19. Gurbel PA, Bliden K P, Butler K, et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation. 2009;120:2577-2585.
20. Wallentin L, Becker RC, Budaj A, et al.; PLATO Investigators. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med. 2009;361:1045-1057.
21. Storey RF, Becker RC, Harrington RA, et al. Pulmonary function in patients with acute coronary syndrome treated with ticagrelor or clopidogrel (from the Platelet Inhibition and Patient Outcomes PLATO pulmonary function substudy). Am J Cardiol. 2011;108:1542-1546.
22. Storey R F, Bliden K P, Patil SB, et al.; ONSET/OFFSET Investigators. Incidence of dyspnea and assessment of cardiac and pulmonary function in patients with stable coronary artery disease receiving ticagrelor, clopidogrel, or placebo in the ONSET/OFFSET study. J Am Coll Cardiol. 2010;56:185-193.
23. Mahaffey KW, Wojdyla DM, Carroll K, et al.; PLATO Investigators. Ticagrelor compared with clopidogrel by geographic region in the Platelet Inhibition and Patient Outcomes (PLATO) trial. Circulation. 2011;124:544-554.
24. Price MJ, Berger PB, Teirstein PS, et al.; GRAVITAS Investigators. Standard-vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: the GRAVITAS randomized trial. JAMA. 2011;305:1097-1105.
25. Bhatt DL, Cryer BL, Contant CF, et al.; COGENT Investigators. Clopidogrel with or without omeprazole in coronary artery disease. N Engl J Med. 2010;363:1909-1917.
26. Goodman SG, Clare R, Pieper KS, et al.; Platelet Inhibition and Patient Outcomes Trial Investigators. Association of proton pump inhibitor use on cardiovascular outcomes with clopidogrel and ticagrelor: insights from the platelet inhibition and patient outcomes trial. Circulation. 2012;125:978-986.
27. Mega JL, Braunwald E, Wiviott SD, et al.; ATLAS ACS 2-TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med. 2012;366:9-19.